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Diabetes is a common chronic illness that affects millions of people in the United States. 
Poorly controlled diabetes can lead to health complications that impact quality of life, 
increase healthcare costs, and create a negative impact on communities. Pharmacological 
management of diabetes was identified by stakeholders as a gap in practice at a clinic in 
the southeastern United States. The purpose of this project was to develop staff education 
based on American Diabetes Association (ADA) and American Association of Clinical 
Endocrinologists (AACE) standards of care, deliver education to primary care nurse 
practitioners (NPs), and evaluate their learning and confidence levels. The primary 
framework for this project was the chronic care model. An expert panel, including 2 
board-certified endocrinologists and a registered nurse diabetic educator, reviewed the 
educational materials and agreed the presentation was clinically appropriate for the 
intended audience and the content was current and accurate. Seven NPs participated in 
the preassessment survey and education program, and six NPs completed the 
postassessment survey. Preassessment and postassessment surveys asked 13 questions 
rated on a Likert-type scale from 5 (very comfortable) to 1 (very uncomfortable). 
Participant responses showed an increase to comfortable and very comfortable on 12 
survey items. Posteducation survey items showed that 100% of participants were very 
comfortable in adjusting premixed insulin, treatment guidelines, and classes of 
medication and their effectiveness. Implications for positive social change related to this 
doctoral project include increased staff knowledge, improved patient outcomes, 
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Section 1: Nature of the Project 
Diabetes is an increasingly common chronic illness. According to the Centers for 
Disease Control and Prevention (CDC, 2016), more than 30.3 million people in the 
United States are currently affected by this chronic illness. In the state of Georgia, 10.7% 
of the population currently suffer from diabetes (CDC, 2016). Poorly controlled diabetes 
can lead to diabetic complications. Patients with diabetes account for more than 30% of 
all noncritical hospitalized patients. The average age of those admitted was 65 years old 
(Ables et al., 2016). The costs of diabetes management, complications, and 
hospitalizations are currently more than 245 billion dollars. The estimated per-person cost 
for diabetes care and associated complications can reach more than $10,000 over 8 years. 
One fourth of that amount can be spent within the first year following diagnosis (Rosella 
et al., 2016). However, many complications and hospitalizations can be decreased or 
prevented starting at the outpatient primary care level.  
Current literature shows that blood glucose control is a critical part of obtaining 
and maintaining long-term health (American Association of Diabetic Educators, 2017). 
Prevention of hyperglycemia in the non-critically ill patient helps to decrease infection, 
complication, morbidity, mortality, and hospital admission (Corsino et al., 2017). 
Metabolic and hormonal changes experienced by patients living with diabetes often lead 
to hyperglycemia, which in turn can lead to immune dysfunction; hemodynamic effects, 
such as dehydration and electrolyte loss; and tissues effects, including inflammation, 





The gap in practice addressed by this doctoral project was the lack of confidence 
in knowledge of nurse practitioners (NPs) to treat their patients with diabetes. This staff 
education program was created with the intention of increasing provider knowledge in 
pharmacological management of diabetic patients using evidence-based practice. This 
project can lead to positive social change by helping providers at the project site increase 
their knowledge and confidence. In turn these providers can use this knowledge to help 
improve patients’ quality of life and long-term health and decrease complications and 
overall diabetes-related healthcare costs (Spruce, 2015) 
Problem Statement 
People with diabetes are three times more likely to be hospitalized than people 
without diabetes. Uncontrolled and recurrent hyperglycemia is a common condition but is 
often preventable with appropriate management (Umiperrez & Pasquel, 2017). The 
healthcare effectiveness data and information set (HEDIS) is a method adopted by 
Medicare and other private payers to determine clinicians’ performance levels. Clinicians 
can be held accountable and receive a decrease in compensation for a failure to meet 
HEDIS measures. HEDIS measures for diabetes are (a) a hemoglobin (A1C) less than 
8%, (b) low-density lipoprotein cholesterol (LDL-C) of less than 100 mg/dL, (c) blood 
pressure (BP) less than 140/90 mmHg, and (d) aspirin therapy in the presence of ischemic 
vascular disease (McCoy et al., 2017). Failure to meet these measures can have dire 
consequences on the patients and the providers. Consequences to the patients include 
poor health outcomes and diabetic complications, such as nephropathy, loss of income 





can experience negative scoring that follows their reimbursement rates under CMS for 
the next year. The project site has experienced a decrease in revenue due to the adjusted 
reimbursement percentage (McCoy et al., 2017). Administrators at the project site stated 
to me that they have not been meeting all their HEDIS measures for diabetes. Many 
patients at the project site are not meeting their A1C goals. There has been an increase in 
patients being admitted to the hospital with diabetic-related complications. Some factors, 
such as patient compliance and ability to afford their medications, are beyond provider 
control. Provider knowledge in pharmacological management of diabetes and confidence 
in that knowledge was the component I sought to address in this DNP project.  
The small private practice in which the project took place is unique in nature. The 
practice provides all aspects of primary care and more to homebound patients. 
Homebound criteria are defined by and set forth by Medicare (Cigna Government 
Services, 2017). Each patient has a different level of physical, mental, emotional, and 
financial ability to see specialists, such as endocrinologists. All project site patients are 
managed by NPs. Several of the providers expressed limited knowledge in the 
management of diabetes, including pharmacological choices and the associated 
pharmacokinetics. I sought to address this important component of patient care in this 
DNP project to help improve patients’ abilities to maintain safe and adequate glucose 
control.  
Purpose Statement 
The purpose of this project was to develop staff education based on American 





(AACE) standards of care, deliver the education to primary care NPs, and evaluate their 
learning and confidence levels. I used the standards of care to create an educational 
program that provided detailed information regarding diabetic pharmacology, 
considerations, mechanism of actions, and a treatment algorithm. The gap in practice 
addressed in this DNP project was the lack of adequate knowledge of pharmacological 
management of diabetic patients by new NPs.  
The practice-focused question that guided this project was: Will an educational 
program presented to primary care NPs on the pharmacological management of diabetic 
patient increase the nurse practitioners perceived confidence and knowledge in treating 
and managing diabetic patients? According to the ADA, each person living with diabetes 
requires individualized treatment plans that best fit each person’s complex needs. The 
goal of this project was to develop a staff education that would help to increase the 
confidence of each provider to properly select the appropriate medications for their 
diabetic patients based on evidence-based practice.  
Overview of the Doctoral Project 
The project site where this staff education project took place is a small primary 
care in-home practice in a major city in southeastern Georgia. Most of the providers are 
new NPs who do not feel they have enough knowledge and experience to properly care 
for and treat diabetic patients. During my tenure as a provider there, I had conversations 
with several of these NPs over the years. These conversations served as a contributing 
factor in creating this DNP project. To answer the practice-focused question, I provided a 





The goal of this DNP project was to increase the confidence and knowledge among NPs 
in a small primary care practice who make house calls to homebound patients. The 
expected outcome was that, following a short but intensive staff education program on 
pharmacological management of diabetic patients, NPs would report a perceived sense of 
increased confidence and knowledge to make timely and appropriate decisions on 
medication management while partnering with their patients. The virtual platform was 
selected as a presentation method due to continued concerns regarding the COVID-19 
global pandemic. The project site continues to provide telehealth services and is 
conducting all meetings virtually. The content of the staff education program provided 
current treatment guidelines, pharmacokinetics, considerations, and contraindications to 
medication therapy and management in the diabetic patient. A pretest survey and a 
posttest survey were given to assess participants’ perceived knowledge and confidence in 
pharmacological management of diabetic patients. A 13-question Likert scale survey I 
created was used to complete the assessment of the participants both before and after the 
staff education intervention. The survey questions were rated on a scale from 0–10 to 
assess the NPs’ level of comfort both before the presentation and after. Descriptive 
statistics were used to analyze the data from the pretest survey and posttest survey.  
The literature review on diabetes was completed using the following key search 
terms: diabetes, nurse practitioner, new provider, confidence, diabetes management, 
insulin, basal, prandial, bolus, glycemic control, hyperglycemia, hypoglycemia, and 
outcomes. Exclusion criteria includes pediatric and gestational diabetes articles and non-





PubMed, NIH, and Embassy. Other sources of evidence included guidelines from the 
ADA and AACE. The search focused on sources written between 2014 and 2020. All 
articles used were peer-reviewed and published within the past 6 years. Exceptions were 
made for appropriate historical articles. Input and opinions from an expert panel 
consisting of two endocrinologists and one registered nurse educator also served as an 
additional source of evidence.  
Significance 
There are 166 endocrinologists in the state of Georgia (Elflein, 2019), which 
makes referrals difficult and accompanied by long wait times. Many patients cannot and 
will not go to a specialist due to an inability to afford medical transport. While working 
as a provider at the project site several patients cited transportation costs to be between 
300 dollars and 700 dollars each way or roundtrip. Many of these patients have 
associated diabetic complications, such as chronic kidney disease, and many have been 
hospitalized due to these complications. It is essential that primary care providers have 
confidence in understanding how to best manage their diabetic patients.  
In this practice, most of the care and pharmacological management of diabetic 
patients is provided by NPs. Therefore, it is essential that these NPs feel confident and 
able to provide evidence-based care that is individualized. Many providers in the primary 
care setting take a one-size-fits-all approach to diabetes management (Rushforth et al., 
2016), which does not incorporate individual patient needs. In-depth training on clinical 
guidelines and the pharmacokinetics of various medications will help practitioners feel 





individualized treatment plan for diabetic patients. This project aligns with DNP 
Essentials I, II, III, and VIII, which address the scientific underpinnings for practice and 
information systems/technology for the improvement and transformation of health care 
(American Association of Colleges of Nursing, 2006).  
The stakeholders for this project include all physicians, NPs, administrators, and 
diabetic patients of the project site. Both physicians and nurses may benefit by increasing 
knowledge on managing these complex patients. The education program supports the 
positive impact of increasing provider confidence in selecting appropriate 
pharmacological management for patients, thereby obtaining better patient outcomes and 
satisfaction. The administrative staff may benefit by seeing an increase in reimbursement 
for services due to meeting HEDIS measures and keeping patients out of the hospital. 
Patients may benefit by experiencing increased quality of life, better outcomes, and fewer 
complications. These benefits illustrate the potential for positive social change.  
Summary 
In Section 1, I provided the introduction to this DNP capstone project. The 
purpose of the project was to provide evidence-based staff education to primary care NPs 
on pharmacological management of patients living with diabetes. Section 1 included an 
overview of the nature of the DNP project, the problem statement, purpose, practice-
focused question, and significance of the project. Section 2 will include a discussion of 
the chronic care model (CCM) as a framework for the DNP project, relevance of the DNP 
project to nursing practice, local background, context, and my role in this project as the 





Section 2: Background and Context 
Millions of people are affected by diabetes, a complex chronic disease. I have 
focused this DNP capstone project on a staff education project to provide 
pharmacological diabetic management education to a group of primary care NPs. In this 
section, I discuss the concepts and models that served as frameworks for this DNP 
project. In addition, I discuss the project’s relevance to nursing, the local background and 
context, and my role as the DNP student. This project was important to the local primary 
care practice. The NPs within the group provide over 97% of all diabetic management for 
their patients. The ADA (2019) standards of care state that treatment modalities in the 
management of diabetes should be timely, based on evidence, and utilize a collaborative 
approach taking into consideration the patients’ prognoses, preferences, and 
comorbidities. The treatment plan should be aligned with the CCM. Primary care 
providers should ensure that treatment plans take into consideration socioeconomic 
factors and use a team–community approach whenever possible (ADA, 2019).  
The purpose of this project was to develop staff education based on ADA and 
AACE standards of care, deliver the education to primary care NPs, and evaluate their 
learning and confidence levels. With this project, I aimed to address an important 
knowledge gap and increase NPs’ confidence in managing their patients by answering the 
practice-focused question. The practice-focused question that guided this project was: 
Will an educational program presented to primary care NPs on the pharmacological 
management of diabetic patient increase the practitioner’s perceived confidence and 





as the major framework for this project. In addition, I discuss the project’s relevance to 
nursing practice, local background and context, my role as the DNP student, and the role 
of the project team. 
Concepts, Models, and Theories 
Chronic Care Model 
The CCM is an evidence-based practice model designed to encourage care teams 
to manage chronic illness using a variety of approaches (Baptista et al., 2016; Stellefson 
et al., 2013). The CCM consists of six components that help guide providers into a 
systematic approach to managing chronic conditions such as diabetes. CCM encourages 
providers to use all resources to manage patients with chronic diseases such as diabetes 
(Baptista et al., 2016; Stellefson et al., 2013). The six components of the CCM are 
purposed to make all resources available through the organization of heath care, while 
minimizing barriers to access to care. The six components include: (a) self-management 
support; (b) decision support and guidance for evidence-based care implementation; (c) 
delivery system design, used for coordinating care processes; (d) clinical information 
systems, used to track progress and to report patient outcomes; (e) community 
information systems, also used to track progress and report outcomes; and (f) community 
resources and polices, which involves use of community-based resources. 
This model is relative to the DNP project because it is used to address the 
importance of support from healthcare organizational leaders. In this project, the 
organizational leadership includes the administrator and medical director. In their support 





and managing quality control issues (Baptista et al., 2016; Stellefson et al., 2013). The 
CCM encourages partnership between the provider and the patient to identify issues, set 
goals, set priorities, and develop plans of care (Baptista et al., 2016). The CCM is the 
primary model of consideration for the ADA. The ADA standards of care are evidence-
based guidelines for primary care providers caring for patients affected by diabetes. The 
primary component of the CCM that is the focus of this project is providing training to 
help create a decision support model for medical practitioners to apply evidence-based 
treatment modalities for diabetic patients. In this case, the primary team members are the 
patient and the provider. The PowerPoint presentation used for the training incorporated 
the ADA standards of care regarding pharmacological management of latent autoimmune 
diabetes in adults (LADA) and Type 2 diabetes mellitus.  
The use of scientifically based clinical guidelines in decision making fosters a 
treatment delivery system that promotes clinical excellence. The CCM is appropriate for 
use in this project as it promotes the support of organization leaders, such as the medical 
director, collaborative physicians, and administration, in identifying necessary resources 
and reducing barriers to practice change that should be evidence based.  
Definition of Terms 
Clinical Inertia: The failure to initiate or intensify treatment when clinically 
indicated (Smith, 2019).  
Socioeconomic Status: A combination of income and occupation used to classify 





Certified Diabetes Care and Education Specialist (CDCES): A licensed professional 
with extended knowledge in diabetes management (CBDCE.org, 2020).  
HbA1C: Hemoglobin A1C blood laboratory tests provide the average blood 
glucose levels over 3 months, which is the period that represents the life of the red blood 
cell (ADA, 2019).  
Microvascular: Involving small blood vessels, such as capillaries, includes 
retinopathy, nephropathy, and neuropathy and results in organ and tissue damage 
(Chawla et al., 2016).  
Macrovascular: Involving large blood vessels, such as arteries and veins, includes 
ischemic heart disease, peripheral vascular disease, and cerebrovascular disease. These 
complications result in organ and tissue damage (Chawla et al., 2016).  
Sodium Glucose Cotransporter 2 Inhibitors (SGLT-I): Oral antidiabetic 
medication that decreases reabsorption of glucose by the kidneys (Hsia et al., 2017).  
Dipeptidyl Peptidase 4 Inhibitors (DPP4): Oral antidiabetic medication that 
inhibits dipeptidyl peptidase (DPP) on the surface of most cells. DPP4 deactivates 
peptides such as GLP-1. DPP4 decreases insulin secretion associated with meals, delays 
gastric emptying, and decreases postmeal glucagon (Dungan & DeSantis, 2020).  
Glucagon Like Peptide 1 Receptor Agonist (GLP-1 RA): Works on GLP-1, which 
is a gastrointestinal peptide that releases glucose in the setting of meals. GLP-1-RA is an 
injectable antidiabetic therapy that works to stimulate insulin synthesis, delays gastric 





Relevance to Nursing Practice 
Primary care NPs are often the first line providers in the management of diabetes. 
Continuing education, clinical competence, and evidence-based practice are the 
cornerstones of quality patient care provided by NPs (Black et al., 2015). The ADA 
(2019) promotes evidence-based treatment plans individualized to each patient. NPs who 
are aware of how each medication works and of considerations for each medication are 
better able to meet this goal.  
Types of Diabetes  
There are multiple types of diabetes. This project focused on medical 
management of LADA and Type 2 diabetes. LADA and Type 2 are the two most 
common forms of diabetes encountered at the project site. Type 2 diabetes is a results of 
cumulative insulin resistance and hyperglycemia, which cause insulin secretion 
deficiencies (ADA, 2018). Type 2 diabetes is one of the most common types of diabetes 
encountered in primary care (Seidu et al., 2020). LADA is a common autoimmune 
disease like Type 1 diabetes in which a patient’s pancreas stops producing adequate 
insulin due to some sort of insult that damages the beta cells of the pancreas (ADA, 
2018).  
LADA is often mistaken for Type 2 diabetes, especially among older adults. 
Because of this, my project did not focus on Type 2 diabetes alone. LADA patients are 
often started on oral agents due to misperception that they have Type 2 diabetes. But oral 





the disease process; LADA patients require insulin and management as though they have 
Type 1 diabetes (Carlsson, 2019).  
Treatment Guidelines 
ADA Standards of Care 
ADA standards of care provide evidence-based guidelines in the treatment and 
management of diabetes. The ADA Professional Practice Committee is comprised of 
healthcare professionals of all types and levels. The Professional Practice Committee 
completes systematic literature searches for new evidence and grade the evidence using a 
rating system. The committee receives feedback during the year and generates the 
standards of care (Chamberlain et al., 2016). These standards of care address (a) 
diagnosis of diabetes, (b) recommendations for glycemic targets, (c) medical 
management of diabetes, (d) risk management for cardiovascular disease, (e) 
microvascular disease management, and (f) diabetic care in hospital (Chamberlain et al., 
2016). In this project I focused on Standard 9 regarding pharmacological approaches to 
glycemic treatment (ADA, 2019). This standard addresses recommendations of initiation 
of treatment.  
The ADA standards of care have developed a treatment algorithm to help guide 
providers in selecting appropriate interventions and medications for diabetic patients. 
This includes lifestyle management as well as the initiation of pharmacological therapy. 
The ADA standards of care provide fundamental guidance for the appropriate selection of 





an addition category of medication and considerations for each. This guideline will be the 
used as the foundational basis of this project.  
The ADA treatment algorithm recommends metformin and comprehensive 
lifestyle changes are as first steps in the treatment of Type 2 diabetes (ADA, 2019). If the 
identified A1C targets are still not met after 3- months providers should consider adding a 
second or third agent. If the patient has a history of atherosclerotic cardiovascular 
disease, chronic kidney disease or heart failure then a Sodium Glucose Cotransporter 2 
Inhibitors (SGLT-2i), Glucagon like peptide 1 receptor agonist (GLP-1 RA) should be 
considered. If Atherosclerotic Cardiovascular (ASCVD) is the dominate condition, then a 
GLP-1 RA should be fist consideration if not contraindicated or an SGLT2i. If chronic 
kidney disease (CKD) or heart failure (HF) are dominate then an SGLT2i should be 
considered if not contraindicated or an GLP-1 RA (ADA, 2019). It is important that 
providers understand the maximum benefits and effects on A1C of each category of 
medication. While the ADA standards of care will be the primary treatment algorithm 
utilized for this project, I will briefly address the AACE treatment algorithm as well. The 
AACE treatment algorithm is not much different than the ADA treatment algorithm. The 
information provided in the algorithm are easy to follow guidelines which providers can 
use to help obtain glycemic control when treating the Type 2 diabetic patient. It gives 
easy to follow numerical A1C recommendations for the initiation of monotherapy, dual 
therapy, triple therapy, and initiation of insulin (American Association of Clinical 





There are subtle differences between the guidance provided in the ADA algorithm 
and that of the AACE algorithm. The AACE recommends an A1C of 6.5% for most 
patients without elevated risk of hypoglycemia. Monotherapy pharmacological 
intervention is recommended for A1C of less than 7.5% (AACE, 2015). The medications 
are listed in order of suggested hierarchy. This hierarchy is further recommended for dual 
and triple therapy. If a patient has an A1C of 7.5% to 9.0% the AACE recommends 
initiating dual or triple therapy initially. This differs from the ADA algorithm which 
suggest starting dual therapy at greater than 9% (ADA, 2019) and triple therapy or 
initiating insulin at 11%. The ADA table is not in order of recommended hierarchy.  
Blood Glucose Levels Related to Pharmacological Management 
The ADA has identified glycemic targets for patients with diabetes. Glycemic 
targets should be individualized for each patient. HgA1C values should be between 6 – 8 
%. The majority of nonpregnant adults should have A1C goals less than 7%. Pregnant 
women should have their A1C maintained less than 6.5%. Those with multiple 
comorbidities, high risk of hypoglycemia, falls, and short life expectancy can have their 
A1C targets relaxed to 8% (ADA, 2019). Daily glycemic values should be kept between 
70 -180 mg/dL with fasting levels kept less than 100 mg/dL for most people (ADA, 
2019). Type 2 diabetes mellitus patients have a variety of pharmacological modalities 
available to treat their diabetes. Each category of medication works on a different 
mechanism, has contraindications, and variable costs. Each category has a maximum 
expected effect on A1C values. It is essential that primary care providers understand: 





recommendations for use for each medication. Lifestyle management and the initiation of 
oral agents are first steps in the management of diabetes.  
Lifestyle Management 
Lifestyle management is the first step in diabetes management. In previous years 
it was recommended that lifestyle management be initiated for Type 2 diabetics at 
diagnosis prior to starting medications. Current guidance is that lifestyle management 
should be initiated at diagnosis along with monotherapy such as Metformin. Lifestyle 
management includes adhering to a low carbohydrate diet which is appropriate diabetics, 
physical activity, smoking cessation, and mental health support. For the purposes of this 
project the focus for lifestyle management will be on medical nutrition therapy and 
physical activity.  
Medical nutrition should be implemented at diagnosis. Medication nutrition 
therapy is nutrition therapy that is provided by registered dietician (Franz et al, 2014). 
Medical nutrition can decrease A1C values by as much as 3%. Utilizing medical nutrition 
therapy provided by a qualified nutritionist can help diabetics to achieve weight loss 
goals, improve glycemic control, improve blood pressure control, improve lipid levels, 
and prevent diabetic complications (Franz et al., 2014). Physical activity is another 
component that can aid in improving overall health, decreasing diabetic complications 
and improving A1C values. For most diabetics, it is recommended to add or increase 
aerobic physical activity to 150 minutes of moderate to vigorous activity weekly. This 
should be achieved over more at least 3 days a week with no more than 2 days off in 






Most medications can be used as monotherapy or adjunctive therapy. Metformin 
(Glucophage) is the initial recommendation for treatment for most diabetic patients (Buse 
et al., 2019). However, some patients are unable to either initiate metformin or they 
cannot tolerate the side effects. In that instance other medications can be used to include, 
Glucagon-like peptide-1 receptor agonists (GLP1-RA), sodium-glucose cotransporter 2 
inhibitors (SGLT2i), dipeptidyl peptidase 4 inhibitors (DPP-4i), thiazolidinediones 
(TZDs), sulfonylureas, and insulin. If an A1C is greater than 9.0% and they have 
symptoms of hyperglycemia, insulin should be initiated either as a stand-alone therapy or 
with other agents (ADA, 2019). Each anti-diabetic agent works on a different component 
of the body.  
Metformin 
Metformin is a biguanide. It is an antidiabetic oral medication used as first line 
treatment in the management of Type 2 diabetes. It works by decreasing hepatic output of 
glucose. Metformin can lower A1C levels by 1-2%. It is a very inexpensive medication. 
Therefore, it is a great consideration for patients that have no insurance or limited 
income. Metformin has been approved for use in pediatric patient older than 10 years. 
Additional benefits to the use of Metformin include cholesterol lowering, no 
hypoglycemia and no weight gain. It cannot be used in those with severely diminished 







Sulfonylureas are another class of oral diabetic medications. These medications 
stimulate the pancreas to make and release insulin. Medications in this class include 
glyburide, glipizide, and glimepiride. Sulfonylureas can lower A1C levels by 1.0-2.0%. 
They are a very low cost and are another good choice for those with no insurance or 
limited incomes. They can cause hypoglycemia and weight gain so they should be used 
with caution in the elderly and very obese (Avramidis et al., 2020).  
Sodium-Glucose Cotransporter 2 Inhibitors  
Sodium-glucose cotransporter 2 inhibitors (SGLT2) are a class of oral antidiabetic 
medications that decrease reabsorption of glucose by the kidneys. They have an A1C 
lowering capability of 0.6 – 1.5%. These medications are able to inhibit the very high -
capacity transporter SLGT2i which is most prevalent in the kidney. SGLT binds to 
sodium and glucose and is responsible for 90% of the glucose reabsorption in the kidney. 
These medications also have cardioprotective benefits and reduce risk of cardiovascular 
death, heart failure and are also renal protective. The benefits include that the patient does 
not experience side effects of hypoglycemia and weight gain. In fact, SGLT2i 
medications often aid in weight loss. Common side effects of SGLT2i drugs include 
hypotension, UTIs, mycotic infections, and ketoacidosis (Shahady & Leahy, 2010).  
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists  
Glucagon-like peptide-1 (GLP-1) receptor agonists are an antidiabetic injectable 
therapy. They are incretin-based therapies that increase the release of insulin during 





food. They can lower A1C levels 0.5 – 1.6%. Most side effects are gastrointestinal and 
generally subside. This category of medication should not be used in patients with a 
familial history of medullary thyroid cancer. GLP-1RAs also reduce risk of 
cardiovascular death, myocardial infarction, stroke, and can aid in weight loss of 1.6 – 
6.0 kg (Almandoz et al., 2020).  
Dipeptidyl Peptidase 4 Inhibitors  
DPP-4i or dipeptidyl peptidase 4 inhibitors are another class or oral antidiabetic 
medication. These medications also work in the incretin hormone. Like the GLP-1, DPP-
4i medications work to increase insulin secretion with food, delay gastric emptying, and 
prolong action of gut hormones. They can lower A1C levels 0.6 – 0.8%. These 
medications do not cause hypoglycemia or weight gain. They have been associated with 
disabling joint pain. This adverse effect will generally subside upon discontinuation of 
the medication.  
Thiazolidinediones  
Thiazolidinediones (TZDs) are a class of oral antidiabetic medication that 
increase insulin sensitivity. They can lower A1C 0.5 – 1.0%. One TZD has been in the 
media over the last few years with a black box warning that it caused bladder cancer. 
This warning has since been redacted and replaced with a warning of increased risk for 
bladder cancer. TZDs may also cause or worsen congestive heart failure as it causes the 






There are a variety of insulins on the market. Insulin therapy is required for Type 
1 DM and LADA. Basal or long- acting insulin is meant to mimic a body’s natural 
release of daily insulin. There are 2 types of basal insulin which are long-acting and 
Intermediate. The difference is in the dosing, manufacturer, duration, and costs. Basal 
insulins last 6-42 hours. Prandial or mealtime insulin come as rapid-acting insulting and 
short-acting insulin. Like basal insulin the difference is onset, duration, costs, and 
manufacturer. Onset is anywhere from 2.5 minutes to 60 minutes and duration of 3-8 
hours (Avrammidis et al, 2020). 
Complications 
According to the CDC 1 in every 10 people have diabetes. This represents 
approximately 30.3 million people (CDC, 2016). Decreased mortality combined with the 
increased prevalence of diabetes means that there are more people living longer with 
diabetes (Green et al., 2016). The incidence of age-related factors such as dementia 
increase with the duration of diabetes. This increases the risk of associated diabetic 
complications. These complications include macro-vascular complications such as 
coronary artery disease (CAD), stroke and peripheral arterial disease as well as 
microvascular complication such as end stage renal disease, retinopathy, and neuropathy 
(Harding et al, 2019). According to Harding et al., (2019), the two most common micro-






Uncontrolled hyperglycemia is the most common cause of microvasculopathy as 
well as macrovasculopathy (Chawla et al, 2016). The importance of glucose control 
cannot be diminished. Early implementation of glucose control through lifestyle and 
pharmacological management as well as continued maintenance greatly contribute to 
minimizing diabetic complications. Poor glucose control contributes to extracellular 
matrix protein synthesis, oxidative stress, and capillary membrane thickening (Chawla et 
al., 2016). These are changes to microvascular and macrovascular complications of 
diabetes. Identification of glycemic targets, meeting those targets and maintaining those 
targets is important in both primary and secondary prevention of complications which can 
lead to blindness, renal failure, myocardial infarction, stroke and increased mortality (Zhu 
et al., 2017). Early management often occurs in the primary care setting. This makes this 
DNP project timely and relevant. The ADA Standards of Care are the most cited and 
utilized guidelines for management of diabetes. Therefore, this will be the primary 
guideline utilized for this training. The ADA Standards of Care have guided the 
management of diabetes in the primary care setting since 1989 (Chamberlain et al., 
2016).  
Local Background and Context 
In the state of Georgia, the number of elderly peoples affected by LADA and 
Type 2 diabetes has grown significantly. According to the Georgia department of Public 
Health, deaths related to diabetes are 8 % higher than the national average (Georgia 
Department of Public Health, 2015). Georgia ranks 38th in the nation for diabetes 





of diabetes, there continues to be vast number of patients that are not reaching their 
identified glycemic goals (ADA, 2019). The estimated per-person costs for diabetes care 
and associated complication were >$10,000 over the course of eight years (Rosella et al., 
2016). Decreasing costs, decreasing negative health outcomes, and increasing positive 
outcomes, as well as increasing provider knowledge and confidence are important factors 
which drove the decision to conduct this DNP project.  
As previously stated, this is a small privately owned primary care practice. The 
owner is an internal medicine MD and as such is a major stakeholder in this project. He is 
a major stakeholder because meeting HEDIS measure, getting the best outcomes for the 
clinic’s patients, helping the NPs feel empowered and supported are positives outcomes 
that will build and enhance this practice. The seven NPs that participated in this 
education project have a variety of experience from new graduate to those with years of 
experience. All patients are seen in their homes or facilities such as assisted living Many 
patients are home bound, therefore have a difficult time seeing specialists due to physical 
issues and the challenges of medical transport. Cost often prohibits special transportation 
to a clinic appointment and there is not access to an endocrinologist. The NPs, as 
providers in this practice, often manage all aspects of their patients’ care. These NPs are 
bridging a gap by providing care to this underserved population. They help to decrease 
cost of care by providing frequent visits, improving access to care, and providing a quick 
response to need (Jones et al, 2017). 
The majority of patients treated by this project site are over 60 years of age. Over 





al, 2016). During internal audits, the Administrator of the practice noticed that many 
patients are not meeting their A1C goals. NPs also self-identified limited knowledge 
regarding some categories of diabetes medications and therefore do not commonly 
prescribe them. This staff education may help to improve NP ability to create 
individualized EBP care plans utilizing a combination of pharmacological approaches. 
Safe and appropriate treatment aimed at adequate glycemic control in diabetes is essential 
in decreasing both individual and societal disease burden (Leon et al., 2015).  
Role of the DNP Student 
I am a master’s prepared registered advanced practice registered nurse with 10 
years of experience. I currently work as a NP and certified diabetic educator in an 
outpatient endocrinology office in a hospital setting. Many primary care physicians, NPs 
and physician assistants refer their diabetic patients to us for consultation and 
management. Through these consults it is evident the lack of knowledge and confidence 
in managing these patients beyond one or two medications. The practice in which this 
project will be completed is a former employer. During my tenure there I saw firsthand 
the complexity of the diabetic patients of the practice as well the limited knowledge, 
confidence, and experience of the providers. The role of a doctoral prepared nurse is to 
improve clinical outcomes for patients through education and example in clinical 
leadership (Richardson et al., 2014).  
I served as the leader of this DNP capstone project. This project was created 
utilizing the treatment guidelines from the ADA and AACE. No personal opinions or 





Steps in the Development of a Staff Education Project  
The diabetes staff education project began with a discussion with the director for 
advance practice providers and the medical director. A current need was identified related 
to NP education on the medical management of diabetic patients. The medical director 
determined that this education program would be a positive tool to help strengthen 
diabetes management for the NPs within the practice. The project was implemented 
during plan is to implement a regularly schedule staff meeting. This staff education 
project followed Walden University’s DNP Manual for Staff Education. I reviewed the 
ADA standards of care, materials from The Association of Diabetes Care & Education 
Specialists (ADCES), and the AACE guidelines to prepare the presentation. I obtained 
Walden University Institutional Review Board (IRB) number 11-16-20-0676748 
approval prior to starting the project.  
Role of the Project Team 
Expert Panel 
Content for the project presentation was reviewed by an expert panel made up of 
two endocrinologists and one registered nurse educator who is also a certified diabetes 
care and education specialist (CBDCES). The panel of experts were presented the power-
point content via email and then provided recommendations for feedback. 
Endocrinologist 1 signed off on the presentation stating he felt it was thorough and 
appropriate for the clinical setting and audience identified. Endocrinologist 2 suggested 
made the following suggestions: “Add that Type 2 diabetes mellitus is usually overweight 





and the daily. Add Rybelsus as we want advocate that GLP1 and SGLT2i provide weight 
loss and cardiovascular benefit so these medications should be on top of list after 
metformin. Add a slide on lifestyle change: exercise 150 minutes per week, weight loss 
of 5% can have significant impact and limit carbohydrate intake to 60 grams per meal.” 
The Registered nurse educator echoed Endocrinologist 2 input.  
I then incorporated the changes into the presentation. The team assembled in our 
clinic meeting room for a review and final discussion of the presentation. The panel 
agreed the presentation was appropriate and ready for dissemination. As leader of this 
DNP project I assumed responsibility for the presentation and sent a finalized copy to the 
medical director of the project site and requested for any input. The only concerns he 
voiced were regarding time management. Originally, a time frame of 45 minutes was 
allotted to complete the presentation. However, due to clinic time constraints he 
requested the information be presented within a 30- minute time slot. I agreed to the 30- 
minute period and moved forward with scheduling the presentation with clinic 
administration.  
Summary 
In Section 2 of the DNP capstone project I discussed the CCM which served as 
the framework to support this project. The need for the project and relevance to nursing 
practice, local context, and the role of the DNP student are explained. In section 3 I will 







Section 3: Collection and Analysis of Evidence 
Section 3 includes the sources of evidence, project design, data collection, and 
survey tool for evaluation of the project. Evidence-based education on pharmacological 
management of the Type 2 diabetic and LADA patient can improve provider confidence, 
knowledge, ability and improve patient outcomes. Several NPs in the practice have 
voiced their lack of confidence in pharmacologic management of these diabetic patients. 
The practice management and physician collaborators are providing the support for the 
project and recognize the need to educate the NPs to provide evidence-based patient care 
and medical management. Section 3 will include discussions of the sources of evidence, 
project design, and the analysis and synthesis of project results.  
Practice-Focused Question 
Diabetes is a global health issue and a local practice problem. This DNP project 
was designed to address the local practice problem within a small primary care practice in 
southeastern Georgia. The practice-focused question that guided this project was: Will an 
educational program presented to primary care NPs on the pharmacological management 
of diabetic patients increase the practitioners’ perceived confidence and knowledge in 
treating and managing diabetic patients? The purpose of this project was to develop staff 
education based on ADA and AACE standards of care, deliver the education to primary 
care NPs, and evaluate their learning and confidence levels. The evaluation of learning 
was completed by providing participants with a Likert-style survey prior to the education 





presurvey and postsurvey were collected and the differences between the two 
assessments were recorded. 
The practice problem is related to the prevalence of diabetes in the state of 
Georgia, burden of cost of care, increase in mortality, and the need for primary care NP 
education to manage the condition. The practice where this project was implemented has 
a high percentage of diabetic patients; approximately one of every four patients are living 
with diabetes. I worked for this practice for 3 years and helped begin implementation of a 
diabetes management program. In my current role working as an endocrinology NP with 
a focus on diabetes, I have been able to observe the knowledge deficit with management 
of diabetic patients in the primary care setting. The NPs at this practice have varying 
degrees of competency regarding pharmacological management of these patients. This 
DNP project was centered around educating NPs on the ADA and AACE guidelines for 
pharmacological management of Type 2 and LADA diabetic patients.  
Sources of Evidence 
Sources of evidence for this project included an exhaustive review of the literature 
for appropriate and reliable information on diabetes management. I searched databases 
such as MEDLINE, CINAHL, Pub Med, CINAHL full text, Ovid Nursing Journals, 
National Institutes of Health (NIH), and EBSCO host. Other sources of evidence included 
guidelines from the ADA and the AACE. Key search terms used were diabetes, Type 2, 
LADA, antidiabetic, medications, SGLT2i, GLP-1 RA, sulfonylurea, metformin, 
treatment, DPP4i, insulin, basal, prandial, bolus, outpatient, primary care, nurse 





published within the last 6 years, evidence-based, peer-reviewed, and published in 
English. Guidelines were from the ADA and AACE. Input and opinions from an expert 
panel also served as a source of evidence. Evidence collected was used to create 
educational intervention appropriate for NPs in a primary care clinical setting. The 
collection and analysis of this evidence provides an appropriate method to address the 
practice-focused question.  
Evidence Generated for the Doctoral Project 
A data source for this project was evidence obtained during an exhaustive search 
of the literature regarding management of diabetes in primary care. Other sources of 
evidence included input and opinions from the expert panel as identified in the previous 
section as well as data from the ADA and AACE. Due to time constraints identified by 
the project site medical director, the education program had to be completed in 30 
minutes. The program was delivered during an already scheduled staff meeting and 
completed on their online meeting platform. I created a 13-question Likert-style survey 
with ratings from 0–5. The surveys asked participants to rate their level of confidence in 
managing each category of medication reviewed in the presentation.  
The preassessment and postassessment surveys were separated by the staff 
education intervention on the pharmacological management of diabetics. As leader, I 
conducted the staff education presentation that incorporated the most current evidence-
based practice guidelines based on the ADA and AACE guidelines. I provided 
information on the most common types of diabetes seen in primary care along with 





including mechanism of actions, maximum benefit, dosage recommendations, 
contraindications, and most common side effects. I encouraged staff participation by 
asking questions pertaining to medications and responding to questions and concerns 
related to the NPs’ specific patient population.  
Six NPs, two medical doctors and two administrative staff of the practice 
participated in the project. The preassessment survey was emailed to the director of 
advanced practice providers the day previous. Only the participating NPs were provided 
with and asked to complete the survey. She assigned each NP that participated a number 
from 1-7. Those results were collected by her prior to the staff education intervention and 
emailed back to me with the words provider number and a number from 1-8 placed in the 
upper right corner. I received seven preassessment surveys prior to the intervention. The 
staff education was completed by sharing the power point along with an oral presentation 
of the information included in the slides. Following the presentation, the staff were asked 
to complete their postassessment surveys and return them. Again, the director collected 
the post assessment surveys and returned them to me via email. I received six 
postassessment surveys. Since each of the surveys were randomized, I was uncertain 
which provider did not return their survey.  
The providers of the project site were informed that by completing and returning 
the pre and post assessment surveys that participation was regarded as consent to 
participate in the project. They were informed that could change their mind about 
participation at any time by not completing the assessments. The staff were informed of 





provided with the opportunity to voice any concerns regarding the project and collection 
of survey data. They were assured that identifies would remain anonymous, private, and 
confidential. There were no further ethical dilemmas anticipated.  
Protections 
The Site Agreement Form Anonymous Questionnaire was signed by the 
Administrator of the practice and submitted with Form A to the Walden IRB for 
approval. The Walden University Institutional Review Board (IRB) approved the project 
and the staff education was completed under IRB number 11-16-20-0676748. The 
diabetes staff education project began with a discussion with the medical director 
regarding the need for provider education on diabetic patient management. The 
educational program focused on pharmacologic management for this patient population. 
The aim of the project was to meet an educational need for providers to feel more 
knowledgeable in the medical management of diabetic patients. The medical director is 
very supportive of the project after determining that this education program would be a 
positive tool to help strengthen diabetes management for the NPs within the practice. The 
project was implemented virtually during a regularly schedule staff meeting. This was at 
the request of the medical director and follows the COVID-19 guidelines for the clinic.  
Analysis and Synthesis 
All providers at the clinic were invited to participate in the educational program 
(Appendix A). Participants were asked to complete a survey to assess pharmacological 
knowledge prior to the education program. Upon completion of the education 





perceived confidence and knowledge on pharmacological management for diabetic 
patients. The pre/post survey consist of 13 questions. Each question was answered using 
a 5-point Likert scale (Appendix B). The Likert scale ranges from strongly disagree to 
strongly agree. All survey results are anonymous to me and will remain confidential. The 
clinical advanced practice director disseminated and collected the surveys, each of which 
were given random numbers and then she returned all the collected surveys to me in one 
email. The project site is located over two hours away from my location. Due to Covid-
19 concerns and the ability to meet in person, this was most proficient way to allow for 
anonymity to the writer given that this will all be completed using virtual platforms and 
email technology I completed a quantitative review of the survey results. The review 
includes the number of study participants and scores from pre and post survey 
assessment. The collected data was analyzed by pairing results for each provider and 
compiling those results in table to compare clinician perceived confidence in their 
knowledge and ability to manage their patients on the various categories of medications.  
Summary 
In this section I focused on the collection and analysis of the evidence, project 
design, and the local practice gap within a small primary care practice in southeastern 
Georgia. I also addressed the practice-focused question that guided this DNP project. The 
potential benefits of this project were to increase NP knowledge and confidence in 
pharmacological management of their diabetic patients. Section 4 includes the evaluation 






Section 4: Findings and Recommendations 
Diabetes is currently one of the most common chronic diseases treated in primary 
care. Understanding evidence-based pharmacological management of these patients is 
essential to preventing associated complications, decreasing hospitalizations, helping 
patients achieve better quality of life, and ensuring practitioners meet HEDIS measures 
that directly affect compensation. During chart reviews, the administrator of the project 
site noted continued increases in the A1C of their diabetic patients as well as increased 
hospitalizations with diabetic complications. Many of the wound care patients the project 
site treats are diabetic, and poor glycemic control greatly contributes to slow wound 
healing. One possible contributing factor to these outcomes identified was limited 
provider knowledge on pharmacological management of diabetic patients. This identified 
gap in practice was addressed through this staff education project.  
The practice-focused question that guided this project was: Will an educational 
program presented to primary care NPs on the pharmacological management of diabetic 
patients increase the practitioner’s perceived confidence and knowledge in treating and 
managing diabetic patients? The purpose of this project was to develop staff education 
based on ADA and AACE standards of care, deliver the education to primary care NPs, 
and evaluate their learning and confidence levels. The sources of evidence used to 
complete this project included an extensive of clinical databases such as MEDLINE, 
CINAHL, Pub Med, CINAHL full text, Ovid Nursing Journals, National Institutes of 
Health (NIH), and EBSCO host. Other sources of evidence included guidelines from the 





Section 4, I discuss project findings, recommendation, strengths, and limitations of the 
project. 
Findings  
This staff educational program (Appendix A) was successful in attaining the goal 
of increasing NP confidence in the pharmacological management of diabetic patients. A 
preassessment survey was provided to the providers of the project site. There were seven 
NPs and two physicians who participated in the program. The preassessment surveys 
were collected by the director prior to the presentation. The education program consisted 
of a PowerPoint presentation and an open question-and-answer session. Instructions were 
given to the participants regarding the completion of the postassessment surveys. Again, 
participants were reassured that participation would be completely anonymous and each 
survey would be returned and reported with a randomly assigned number from 1–9. The 
education program session lasted approximately 35 minutes. The postassessment surveys 
were collected by the director and returned to me via email. Each set of preassessment 
and postassessment surveys were paired with an assigned provider number. The results of 
each were compiled in a table and the results reviewed and compared to answer the 
practice-focused question.  
Preassessment 
Table 1 presents a summary of the data from the preassessment survey (see 
Appendix B). At the beginning of the presentation, I explained to the providers that the 
purpose of the presentation was to increase provider knowledge and confidence in the 





preintervention self-evaluation of provider knowledge and confidence in the 
pharmacological management of their diabetic patients. Seven (n = 100%) NPs 
completed the preassessment evaluation. The MDs reported that they would participate in 
the presentation but not in the survey. The self-evaluation was presented in a written 
Likert-scale format. The options were numbered 1–5 for very comfortable, somewhat 
comfortable, neutral, somewhat uncomfortable, and very uncomfortable. 
The self-assessment questionnaire consists of the following 13 questions: 1) 
providers were asked what their general levels of comfort was in adjusting basal insulin.; 
2) providers were asked what their general level of comfort was in adjusting prandial 
insulin; 3) providers were asked what their general level of comfort was in adjusting pre-
mixed insulin; 4) providers were asked their level of comfort with ADA/AACE treatment 
recommendations; 5) providers were asked their level of comfort with which oral and 
injectable therapies could be combined; 6) providers were asked their level of comfort in 
their knowledge of the maximum effects each class of medication has on A1C values; 7) 
providers were asked their level of comfort with the metformin; 8) providers were asked 
their level of comfort with sulfonylureas; 9) providers were asked their level of comfort 
with DPP4i medications; 10) providers were asked their level of comfort with SGLT2i 
medications; 11) providers were asked their level of comfort with GLP1RA medications; 
12) providers were asked their level of comfort with thiazoldinediones; 13)providers 






Question 1 Four NPs (57%) selected 3 for both Questions 1 and 2, indicating that 
they felt neutral about their knowledge and confidence in adjusting basal and prandial 
insulin. Two NPs (29%) selected 4 for both Questions 1 and 2, indicating they felt 
somewhat comfortable about their knowledge and confidence in adjusting basal and 
prandial insulin. One NP (14%) selected 5 for both Questions 1 and 2, indicating they felt 
very comfortable about their knowledge and confidence in adjusting basal and prandial 
insulin.  
The data showed that two NPs (29%) stated they felt very comfortable with 
recommending lifestyle management, Question 3, to their patients. Three NPs (43%) 
selected 4, and two NPs (29%) selected 3 for their response. Three NPs (43%) selected 4 
for both Questions 4 and 5, and four NPs (57%) selected 2, reporting they felt very 
uncomfortable with ADA/AACE treatment recommendations and combining oral and 
injectable medications. Two NPs (14%) selected 3 for Question 6, and five NPs (71%) 
selected 2. Question 7 seemed to be the area in which most of the NPs felt most 
comfortable. Six NPs (86%) selected 1, and one NP (14%) selected 2. Three NPs selected 
4 (57%) for Question 8, two NPs (29%) selected 3, and two NPs (29%) selected 2. Two 
NPs (29%) selected 4 for Question 9, three NPs (43%) selected 3, and two NPs (29%) 
selected 2. One NP selected 4 for Question 10, three NPs (43%) selected 3, two NPs 
(29%) selected 2, and one NP (14%) selected 1. Three NPs (43%) selected 3 for Question 
11. Two NPs (29%) selected 3, four NPs (57%) selected 2, and one NP (14%) selected 1 
for Question 12. Two NPs (29%) selected 4 for Question 13. Three NPs (43%) selected 3, 



















Q1 1 (14) 2 (29 4 (57)   
Q2 1 (14) 2 (29) 4 (57)   
Q3 2 (29( 3 (43) 2 (29)   
Q4  3 (43) 4 (57)   
Q5  3 (43)  4 (57)  
Q6   2 (29) 5 (71)  
Q7 6 (86) 1 (14)    
Q8  3 (43) 2 (29) 2 (29)  
Q9  2 (29) 3 (43) 2 (29)  
Q10  1 (14) 3 (43) 2 (29) 1 (14) 
Q11   3 (43) 3 (43) 1 (14) 
Q12   2 (29) 4 (57) 1 (14) 
Q13  2 (29) 3 (43) 2 (29)  
Note. VC = Very comfortable, SC = Somewhat comfortable, N = Neutral, SU = 
Somewhat uncomfortable, VU = Very uncomfortable.  
 
Postassessment 
After the power-point presentation the providers were given time for a question 
and answer session. Once the providers exhausted their questions, they were invited to 
again complete Appendix B as a post-education self-assessment. Table 2 represents the 
results of the post-education self-assessment survey. Only six NPs returned the post-
education self-assessment survey to the director. The assessments were paired with 
anonymous numbers 1-7. Participant 5 did not return their post-education self-
assessment. Therefore, the post-education survey is N=6.  
The data showed improvement in all areas of the survey. Four NPs (67%) selected 
number 5 for question 1 and two NPs (33%) selected number 4. The data showed that 





NP (17%) selected number 3. All six NPs (100%) selected number 5 for questions 3 and 
4. Five NPs (83%%) selected number 5 for question 5 and one NP (17%) selected 
number 4. The data shows that all six NPs (100%) selected number 5 for questions 6, 7, 
8, 9, 10, 11 and 12. Five NPs (83%) selected number 5 for question 13 and one NP (17%) 
selected number 4.  
Table 2 
 












Q1 4 (67) 2 (33)    
Q2 3 (50) 2 (33) 1 (17)   
Q3 6 (100)     
Q4 6 (100)     
Q5 5 (83) 1 (17)    
Q6 6 (100)     
Q7 6 (100)     
Q8 6 (100)     
Q9 6 (100)     
Q10 6 (100)     
Q11 6 (100)     
Q12 6 (100)     
Q13 5 (83) 1 (17)    
Note. VC = Very comfortable, SU = Somewhat comfortable, N = Neutral, SC = 
Somewhat uncomfortable, VU = Very uncomfortable. 
 
This staff education project demonstrated that providing NPs in a small primary 
care office with education on the pharmacological management of the diabetic patients 
increases their confidence in their knowledge and ability to manage those patients. The 
results of this study align with the goals of the CCM which seeks to create systems to 
enhance diabetes management in the primary care setting by bridging the gap between 





project met the purpose which was to develop staff education based on ADA and AACE 
standards of care, deliver the education to primary care NPs, and evaluate their learning 
and confidence levels. 
The primary goal is for NPs to utilize this knowledge and confidence to partner 
with their patients to design individualized treatment plans. This will help to improve 
patients’ quality of life, help the project site to meet HEDIS measures, and decrease the 
socio-economic cost burden associated with poor diabetic outcomes. Knowledge and 
confidence will allow each provider to address patient cultural beliefs, financial needs, 
comorbidities and emotional concerns when generating an individualized treatment plan 
(Germossa et al., 2018).  
Recommendations 
Primary care knowledge and confidence in selecting appropriate pharmacological 
agents for their diabetic patients is an important component is diabetic management. 
Gerald et al., (2010) proposes that structured nursing education should be conducted 
through continuous training programs which enhance proficiency and help nurses to keep 
up to date with current evidence-based practices in the management of diabetes. I 
recommend that a recurring education program on diabetes management which includes 
scenarios and perhaps real time case reviews be implemented at the project site. In 
addition, a regularly scheduled review of HEDIS measures and goals may prove to be 
beneficial. This will allow the project site providers to better understand how effective 
the interventions they are selecting for their diabetic patients have been. Another 





diabetic management and care. This will allow the providers to spend quality time not 
only reviewing labs and medications but to discuss other lifestyle modifications and 
provide intensive diabetic education to their homebound patients. 
Strengths and Limitations of the Project 
A major strength to this DNP project was that the medical director and 
administrative director were supportive of the project. The providers were receptive to 
the information and felt the information was useful and applicable to their practice. The 
presentation was easy to follow, evidence-based and up-to-date. A major limitation of 
this project was the limited sample size. Only 7 NPs participated in the education and 
only 6 completed both pre and post self-evaluation assessments. The project was 
completed at a single site. The larger sample size or multiple sites may yield different 
results. Therefore, it is impossible to generalize the findings. Another limitation was the 
allotted time. I was given 30 minutes to complete the project. While I was able to 
complete within the timeframe more time would have allowed for the providers to truly 
process the information and allotted for a more robust questions and answer session. The 
way the surveys were dissemination and collected could be considered a limitation.  
Section 5: Dissemination Plan 
 
Section 5 is the final phase of the DNP project. The focus of this section is the 
dissemination of findings. In this section, I include self-reflection and analysis as well as 
a review of the dissemination plan for the results of the project. The aim of the project 
was to generalize the education for use in outpatient clinics, hospitals, and other 





potential to empower primary care NPs and other providers to create pharmacological 
care plans individualized to each patient. This improves patient outcomes and enhances 
quality of life.  
Dissemination 
This project was created and delivered using evidence-based guidelines from the 
ADA and AACE. I provided the project site with an emailed copy of the PowerPoint 
presentation used in the staff education program. Providing the materials helps to 
promote continuing education by allowing them ease of access to the material. The 
project site can then use the presentation to conduct refresher training for current staff 
and initial training for new hires. It will be the responsibility of the directors and each 
provider to remain up to date with current literature and changes in treatment standards. 
The project site can also use the information to create handouts for their providers to use 
as a quick resource. The preassessment and postassessment surveys indicated that the 
NPs who participated in the education program experienced an increase in knowledge on 
the pharmacological management of diabetic patients. The participating NPs also 
experienced an increase in confidence levels to manage and select appropriate medication 
for patients. All participants were asked to provide feedback on the quality of the 
presentation.  
Analysis of Self 
My passion for diabetes began while working as a field NP with this project site a 
few years ago. It was during my tenure at this practice that I began to understand how 





medication could be beneficial to my patients. Many of the patients are on fixed or 
limited incomes and out-of-pocket costs are a major consideration. It was disheartening 
to see patients return from the hospital with care plans I knew they would never be able 
to follow. This inability to adhere to a care plan would often lead to rehospitalizations. 
These experiences were the driving force behind my passion for helping those living with 
diabetes experience a good quality of life. I have worked diligently to understand the 
pharmacodynamics of medications and learned the out-of-pocket costs associated with 
various insurances. Educating primary care staff and their patients to help improve 
patient outcomes is my main goal.  
As a scholar, I use evidence-based practice to create effective educational 
interventions for providers. The goal is for those providers to take what they have learned 
and use the knowledge to treat and educate their patients and other healthcare staff. 
Healthcare is an ever-changing landscape. It is essential that providers seek educational 
opportunities to resolve knowledge gaps. The purpose of this project was to develop staff 
education based on ADA and AACE standards of care, deliver the education to primary 
care NPs, and evaluate their learning and confidence levels. I met this purpose and 
achieved my scholarly goals for this DNP project.  
As the project leader I was able to effectively lead a team of subject matter 
experts. During my time as a DNP student and throughout this project I have grown 
greatly in patience and communication. COVID-19 created some interesting hurdles. 
Through effective communication and collaboration with the project site leadership I was 





project served as a reminder of the importance of remaining up to date on the literature 
and research regarding diabetes. Teaching other providers is very rewarding. I intend to 
put the knowledge and skills developed during the DNP experience to good use. It has 
enforced my faith in my own leadership abilities which I intend to use to teach and train 
current and future generations of NPs.  
Summary 
This DNP project served to educate NPs about the pharmacological management 
of diabetes patients. Utilizing the ADA and AACE guidelines demonstrated to those that 
participated how they can use EBP in their own practice when treating their diabetic 
patients. As society continues to navigate a new normal and learn how to deliver in-
services, hold meetings, and continue social distancing, the use of online media and 
power-point presentations are valuable tools. Based on the findings of this project, the 
creation of a routine staff education component would be beneficial to the project site. 
The findings of the pre and post assessment survey show that NPs did indeed increase 
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Appendix B: Pre/Post Assessment 
I. Self-Assessment: Insulin Therapies  
Directions: The following statements assess your comfort with managing insulin therapy 
in the home. Please rate yourself on a scale from 1-5 with 0 = VERY 
UNCOMFORTABLE to 5 = VERY COMFORTABLE. Circle the number that BEST 
describes you. (Comfort is defined as a feeling of ease in performing the following 
skills). 
1. General level of comfort in adjusting subcutaneous basal insulin  
0........1........2........3........4........5 
2. General level of comfort in adjusting subcutaneous prandial insulin 
0........1.........2........3........4.........5 
3. General level of comfort in adjusting pre-mixed insulin therapy  
II. Self-Assessment oral and injectable therapies  
Directions: The next series of statements assess your comfort with managing oral and 
injectable therapies. Please rate yourself on a scale from 1-5 with 0=VERY 
UNFAMILIAR to 5=VERY FAMILIAR. Comfort is defined as a feeling of ease in 
performing the following skills). 
4. General level of comfort with ADA/AACE treatment recommendations 
0........1........2........3........4........5 







6. General level of comfort with maximum effects each class of medication has on 
A1C 
0........1........2........3........4.........5 
7. General level of comfort with Metformin 
0........1........2........3.........4.........5 
8. General level of comfort Sulfonylureas 
0........1........2........3........4........5 
9. General level of comfort with Dipeptidyl peptidase 4 (DPP-4)  
0........1........2........3........4........5 
10. General level of comfort with Sodium Glucose Cotransporters 2 Inhibitors 
0........1........2........3........4........5 
11. General level of comfort with Glucagon Like Peptidyl 1 Receptor Agonists 
0........1........2........3........4........5 
12. General level of comfort Thiazolidinediones 
0........1........2........3........4........5 
13. General level of comfort with selecting medications that are cardio and renal 
protective (GLP-1RA and SGLT2i)  
0........1........2........3........4........5 
 
